Semaglutid (Ozempic® / Wegovy®): Die Abnehmspritze – Wirkung, Nebenwirkungen, Kosten & was nach dem Absetzen passiert

Contents

1. At a Glance: Key Facts
2. Ozempic vs. Wegovy: What Is the Difference?
3. How It Works: What GLP-1 Does in the Body
4. Indications
5. Dosage & Titration
6. Side Effects
7. What Happens After Stopping?
8. Interactions
9. Semaglutide vs. Tirzepatide (Mounjaro)
10. Cost & NHS Coverage
11. Pregnancy & Special Groups
12. Real-World Data
13. How brite Supports You
14. Semaglutide Experiences: What Users Really Ask
15. FAQ: Frequently Asked Questions About Semaglutide
16. Sources

GLP-1 receptor agonists should only be used under medical supervision. This is not a lifestyle product. This article does not replace medical advice.

1. At a Glance: Key Facts

Semaglutide is the active substance behind Ozempic and Wegovy — two medications that have fundamentally changed the treatment of type 2 diabetes and obesity. With an average weight loss of 15% of body weight over 68 weeks (STEP-1 trial), semaglutide is the most effective weight-reduction agent ever evaluated in clinical trials. It also has demonstrated cardiovascular protection (SELECT trial 2023): 20% fewer major cardiovascular events in obese patients without diabetes.

2. Ozempic vs. Wegovy: What Is the Difference?

The question is valid — because the confusion is widespread: both contain exactly the same active substance, semaglutide. The difference lies in the licensed indication, the maximum dose, and the route to access. Ozempic was developed and licensed for type 2 diabetes. Wegovy was developed specifically for obesity, at a higher dose (2.4 mg instead of max. 2 mg) with weight loss as the primary endpoint.

Why Ozempic should not be used off-label as a weight-loss injection

Since Ozempic became known through social media trends as the "celebrity weight-loss jab", many are seeking it off-label for weight loss without diabetes. This has real consequences: Ozempic has experienced supply shortages in the UK, because people without diabetes have been using supplies intended for those who need it for blood glucose control. People with type 2 diabetes, who depend on Ozempic for their condition, have sometimes been unable to access their medication. The appropriate route for weight reduction with semaglutide is Wegovy — which has its own licensed indication, its own supply chain, and is available through NHS specialist services.

3. How It Works: What GLP-1 Does in the Body

GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after a meal. It signals to the body: "Food has been consumed — produce insulin, reduce glucagon, slow gastric emptying." In nature, GLP-1 is broken down within minutes. Semaglutide is a pharmacologically optimised version of GLP-1 — structurally modified so that it binds to albumin in the blood and therefore remains active for approximately 7 days.

The central effect: less hunger in the brain

Semaglutide's strongest effect is not in the stomach, but in the brain. GLP-1 receptors are also located in the hypothalamus — the appetite and satiety centre. Semaglutide reduces hunger there and suppresses cravings — particularly for calorie-dense, highly processed foods. Many patients report that food suddenly feels "less interesting" or that they feel full after small portions. This is not willpower — this is pharmacology.

4. Indications

5. Dosage & Titration

Stepwise dose escalation (titration) with semaglutide is not optional — it is critical for tolerability. The most common side effect (nausea) occurs mainly when the dose is increased too quickly. Following the titration steps correctly results in considerably fewer gastrointestinal complaints.

Wegovy® titration schedule (obesity)

6. Side Effects

The most common side effects of semaglutide are gastrointestinal, arising from the slowed gastric emptying. For most patients they are temporary — improving significantly after 4–8 weeks. Two rarer but clinically important side effects deserve particular attention: gallstones and muscle loss.

Muscle loss: the underestimated risk of the weight-loss injection

This is the side effect that receives the least attention — despite being significant in the long term. When people lose weight on semaglutide, a substantial portion of that weight loss is lean mass, not fat. Studies show that approximately 30–40% of total weight loss may be muscle mass. This is not specific to semaglutide — it is a general consequence of calorie-restricted weight loss. But the scale of weight loss achieved on semaglutide makes it clinically relevant.

What muscle loss means: reduced strength and endurance, long-term increased risk of sarcopenia (age-related muscle wasting), a lower basal metabolic rate (making future weight management harder), and an increased fall risk in older patients. The countermeasures are clear and evidence-based: a high-protein diet (1.2–1.5 g protein per kg body weight daily) and regular resistance training throughout the therapy. Using the injection without these supportive measures does not optimise results.

7. What Happens After Stopping?

This is the uncomfortable truth about semaglutide — and information that most patients receive too late: after stopping, most people regain weight rapidly.

Why the weight returns — and why so quickly

Semaglutide does not treat the underlying cause of obesity — it modulates hormonal signals that regulate hunger and satiety. While it is in the body, less food is consumed. When it is stopped, the original hunger signals return — often more intensely than before, because the body has responded to caloric restriction. Studies (STEP-4 withdrawal study) show: patients who switched from the therapeutic dose to placebo after 68 weeks on semaglutide regained approximately two thirds of the weight lost within a year.

8. Interactions

The most important interaction is with insulin and sulphonylureas: semaglutide improves blood glucose control, which means doses of these medications often need to be reduced to avoid hypoglycaemia. A clinically underestimated interaction: the slowed gastric emptying can affect the absorption of other medications. Check all combinations with the interaction check.

9. Semaglutide vs. Tirzepatide (Mounjaro): The Comparison

Tirzepatide (Mounjaro) is the direct competitor to semaglutide — and pharmacologically one step further. While semaglutide only activates GLP-1 receptors, tirzepatide simultaneously activates GLP-1 and GIP receptors (dual agonist). GIP is another gut hormone that promotes insulin secretion and acts directly on fat cells. This dual action explains why tirzepatide shows somewhat stronger weight loss in trials.

The verdict: tirzepatide achieves slightly greater weight loss but has less long-term experience and no cardiovascular endpoint evidence yet. Semaglutide remains the first choice with the strongest evidence base. The decision between the two is made by the doctor together with the patient based on starting situation, comorbidities, and individual tolerability.

10. Cost & NHS Coverage

For many patients this is the most practically important question. The current position in the UK:

NICE approved Wegovy for NHS use in 2023 (TA875) for adults with obesity meeting specific criteria, but NHS access is being rolled out through specialist weight management services. Availability via GP is currently limited — a phased expansion is underway. The SELECT trial (2023) demonstrating a 20% reduction in major cardiovascular events is driving broader policy discussion about access. Until wider NHS availability: many patients access Wegovy privately.

11. Pregnancy & Special Groups

Children and adolescents: Wegovy is licensed from age 12 for obesity, under medical supervision. Breastfeeding: not recommended — semaglutide passes into breast milk.

12. Real-World Data: What brite Users Report

13. How brite Supports You with Semaglutide

• Insulin dose warning: Warns of hypoglycaemia risk with insulin and sulphonylurea combinations. → Interaction check
• Titration support: Reminds about stepwise dose escalation and optimal injection days. → Dose reminder
• Pill interaction alert: Warns of altered absorption of oral contraceptives and increased fertility.
• Side effect tracker: Documents GI symptoms and weight progress.
• Muscle loss warning: Actively recommends protein and resistance training.
• Digital medication plan: → Create medication plan

Semaglutide Experiences: What Users Really Ask

Ozempic Wegovy difference — does it matter which I have? Yes — but the difference is not in the active substance, it is in the licensed indication and access route. Ozempic is licensed for diabetes and prescribable on the NHS for that indication. Wegovy is licensed for obesity — available via specialist weight management services or privately. Anyone without diabetes who wants to lose weight should be prescribed Wegovy, not Ozempic. Off-label prescribing of Ozempic for weight loss in people without diabetes is ethically and practically problematic, as it impacts supply for those who need it clinically.

Semaglutide muscle loss — how much and what to do about it? Studies show approximately 30–40% of weight loss may be lean muscle mass. With 15 kg of weight loss, that could be 4.5–6 kg of muscle. That sounds substantial — and it is, if nothing is done about it. The solution is evidence-based: a high-protein diet (1.2–1.5 g/kg body weight daily) and progressive resistance training 2–3 times per week. Consistently following this can substantially reduce muscle loss.

Ozempic stopping weight regain — how quickly does it come back? According to the STEP-4 withdrawal study, patients regain on average approximately two thirds of the weight lost within a year of stopping Wegovy. The reason: the hunger signals return, because the underlying condition (obesity) has not been resolved. This does not mean semaglutide was ineffective — but it does mean that without sustainable lifestyle changes, weight reduction is not permanent.

Semaglutide nausea how long? Most patients report that nausea is strongest in the first 4–8 weeks and then improves significantly. It occurs mainly at the point of dose escalation. Practical tips: small, frequent meals rather than large portions; eat slowly; avoid fatty and strongly spiced foods; drink adequate fluids. Following the titration steps without skipping produces considerably less nausea.

Wegovy NHS — can I get it on the NHS? NICE approved Wegovy for NHS use in 2023 (TA875). However, access is currently being rolled out gradually through specialist NHS weight management services — it is not yet routinely available via GP prescription. Criteria include BMI ≥ 35 (or ≥ 30 with weight-related comorbidities), and referral via a specialist pathway. Many people are currently accessing it privately. Check with your GP or local weight management service about availability in your area.